Zacks Research Issues Pessimistic Estimate for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Research analysts at Zacks Research dropped their Q2 2025 earnings per share estimates for Ironwood Pharmaceuticals in a report issued on Thursday, March 20th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $0.01 for the quarter, down from their prior estimate of $0.04. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.24 EPS and FY2027 earnings at $0.36 EPS.

Several other analysts also recently commented on IRWD. Craig Hallum reduced their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, January 22nd. JMP Securities reduced their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a report on Thursday, January 30th. Finally, StockNews.com downgraded Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $8.60.

Remove Ads

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD remained flat at $1.46 on Monday. 1,336,033 shares of the company's stock traded hands, compared to its average volume of 2,338,684. The company has a market cap of $233.64 million, a PE ratio of -48.67 and a beta of 0.37. The stock's fifty day moving average is $2.13 and its 200 day moving average is $3.42. Ironwood Pharmaceuticals has a 12-month low of $1.34 and a 12-month high of $9.01.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares of the company's stock, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas A. Mccourt sold 139,064 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 192,381 shares of company stock valued at $338,591. 12.90% of the stock is currently owned by company insiders.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV lifted its holdings in shares of Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 3,198 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Ironwood Pharmaceuticals by 150.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,289 shares of the biotechnology company's stock worth $520,000 after purchasing an additional 75,917 shares in the last quarter. Intech Investment Management LLC bought a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $181,000. Charles Schwab Investment Management Inc. boosted its position in Ironwood Pharmaceuticals by 23.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company's stock valued at $7,846,000 after buying an additional 364,841 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in shares of Ironwood Pharmaceuticals by 21.2% during the third quarter. Daiwa Securities Group Inc. now owns 67,570 shares of the biotechnology company's stock worth $278,000 after buying an additional 11,800 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.